Association of XRCC1 genetic polymorphism (Arg399Gln) with laryngeal cancer: a meta-analysis based on 4,031 subjects

Several case–control studies on the relation between XRCC1 gene Arg399Gln polymorphism and laryngeal cancer do not have similar conclusions. To further evaluate the relation between the XRCC1 gene Arg399Gln polymorphism and laryngeal cancer, we selected seven case–control studies related to the XRCC1 gene Arg399Gln polymorphism and laryngeal cancer by searching MEDLINE, EMBase, Chinese Biomedical Literature Database, Chinese CNKI, and Wanfang database. We utilized Q test and I 2 test to test the heterogeneity between each study. The fixed effects model was utilized to calculate the odds ratio (OR) and 95 % confidence interval. The present study included 1,654 patients with laryngeal cancer and 2,377 cancer-free control subjects. By meta-analysis, we did not find any association of XRCC1 gene Arg399Gln polymorphism with laryngeal cancer (OR = 1.13, 95 % CI 0.81–1.58, P = 0.47). Therefore, we concluded that XRCC1 gene Arg399Gln polymorphism was not associated with laryngeal cancer.